

# GEMMs as preclinical models for testing pancreatic cancer therapies

Aarthi Gopinathan<sup>1,\*</sup>, Jennifer P. Morton<sup>2</sup>, Duncan I. Jodrell<sup>1</sup> and Owen J. Sansom<sup>2,\*</sup>

## ABSTRACT

Pancreatic ductal adenocarcinoma is the most common form of pancreatic tumour, with a very limited survival rate and currently no available disease-modifying treatments. Despite recent advances in the production of genetically engineered mouse models (GEMMs), the development of new therapies for pancreatic cancer is still hampered by a lack of reliable and predictive preclinical animal models for this disease. Preclinical models are vitally important for assessing therapies in the first stages of the drug development pipeline, prior to their transition to the clinical arena. GEMMs carry mutations in genes that are associated with specific human diseases and they can thus accurately mimic the genetic, phenotypic and physiological aspects of human pathologies. Here, we discuss different GEMMs of human pancreatic cancer, with a focus on the Lox-Stop-Lox (LSL)-*Kras*<sup>G12D</sup>; LSL-*Trp53*<sup>R172H</sup>; *Pdx1-cre* (KPC) model, one of the most widely used preclinical models for this disease. We describe its application in preclinical research, highlighting its advantages and disadvantages, its potential for predicting clinical outcomes in humans and the factors that can affect such outcomes, and, finally, future developments that could advance the discovery of new therapies for pancreatic cancer.

**KEY WORDS:** Co-clinical trials, Preclinical mouse models, Pancreatic ductal adenocarcinoma, PDAC, Drug discovery, Drug development

## Introduction

Pancreatic cancers are a group of diseases that affect both the endocrine and exocrine compartments of the pancreas. The most common of these is pancreatic ductal adenocarcinoma (PDAC), an exocrine malignancy that accounts for >90% of all cases of pancreatic cancer (Feldmann and Maitra, 2008; Warshaw and Fernandez-del Castillo, 1992). PDAC is a lethal disease, with a 5-year survival rate of <5% (Hidalgo, 2010), and is the fourth leading cause of cancer-related deaths in the United States, with 48,960 new cases and 40,560 deaths estimated in 2015 (Siegel et al., 2015; Warshaw and Fernandez-del Castillo, 1992). In the United Kingdom, it is the fifth most common cause of cancer-related mortality, with 8773 newly diagnosed cases in 2011 and 8662 deaths in 2012 (Cancer Research UK, <http://www.cancerresearchuk.org/cancer-info/cancerstats/types/pancreas/>; accessed August 2015).

In humans, the most frequent genetic alteration that underlies PDAC is an activating mutation of the *KRAS* oncogene (see Box 1), which occurs in >90% of tumours (Almoguera et al., 1988; Biankin et al., 2012). In addition, inactivation of the cyclin-dependent kinase inhibitor 2A (*CDKN2A*) locus, point mutations in tumour protein p53 (*TP53*) and mutations or deletions of SMAD (Sma/mothers against decapentaplegic) family member 4 (*SMAD4*) are commonly found in PDAC tumours (see Box 1) (Hruban et al., 2001b). Disease progression occurs through a series of pre-invasive pancreatic intraepithelial neoplasia (PanIN), which are graded according to their severity of dysplasia and nuclear atypia (see Box 2) (from PanIN-1, the least severe grade, to PanIN-3, which is considered ductal carcinoma *in situ* and is the last grade before invasive carcinoma). These neoplasia grades are also well replicated in animal models (Fig. 1) (Hruban et al., 2001a, 2004). Histologically, PDACs are primarily glandular, although sarcomatoid, colloid and adenosquamous (see Box 2) tumours also occur (Hruban and Adsay, 2009). These tumours are characterized by a dense desmoplastic stroma, consisting of extracellular matrix proteins – such as collagens, laminin and fibronectin – together with fibroblasts and immune cells (Adler, 2004). Early dissemination is also a common feature of PDAC, with primary tumours exhibiting perineural, vascular and lymphoid invasion (Hezel et al., 2006).

The poor prognosis associated with PDAC can mostly be attributed to the lack of its early detection. At first diagnosis, most affected individuals present with advanced and metastatic disease, with less than 20% of patients diagnosed with resectable tumours (Heestand et al., 2015). Metastatic pancreatic cancer is associated with a median survival of less than 6 months on gemcitabine-based chemotherapy (Hidalgo, 2010) (Box 2). Gemcitabine was approved as a standard of care for treating this cancer because it provided a modest survival benefit and improvements in quality of life, compared to treatment with another chemotherapeutic, 5-fluorouracil, in a Phase 3 study (Burris et al., 1997) (Box 2). More recently, Phase 3 studies have demonstrated that the chemotherapy combinations of FOLFIRINOX (Fluorouracil/Oxaliplatin/Leucovorin/Irinotecan) and gemcitabine/nanoparticle albumin-bound (nab)-paclitaxel (see Box 2), result in improved survival over treatment with gemcitabine alone (Conroy et al., 2011; Goldstein et al., 2015; Von Hoff et al., 2013). In late 2013, the combination of gemcitabine and nab-paclitaxel was approved by the Food and Drug Administration (FDA) in the United States for the first-line treatment of metastatic PDAC. Although FOLFIRINOX and gemcitabine/nab-paclitaxel are promising recent developments in the treatment of PDAC, their benefit in terms of survival is limited to months, and therefore there is still a need to develop other novel drugs and combinations to treat this disease.

Novel therapies are identified through the drug discovery and development process, which is outlined in Fig. 2. In this process, the preclinical phase acts as a bridge to the clinic, allowing promising

<sup>1</sup>Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK. <sup>2</sup>Cancer Research UK Beatson Institute, Glasgow, G61 1BD, UK.

\*Authors for correspondence (Aarthi.Gopinathan@cruk.cam.ac.uk; o.sansom@beatson.gla.ac.uk)

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0/>), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

### Box 1. Commonly mutated genes in human pancreatic cancer

#### **KRAS (Kirsten rat sarcoma viral oncogene homolog)**

The *KRAS* gene encodes a protein that plays an essential role in cell signalling in normal tissue, through its activity as an 'on/off' switch for many signal transduction pathways, particularly those regulating cell division. Activating mutations in pancreatic tumorigenesis cause *Kras* to be constitutively active, which makes cells grow and divide in an uncontrolled manner.

#### **CDKN2A (cyclin-dependent kinase inhibitor 2A)**

The *CDKN2A* locus is responsible for encoding two tumour suppressor proteins: p16<sup>INK4a</sup> and p14<sup>ARF</sup>. p16<sup>INK4a</sup> blocks aberrant cell growth and division. Inactivating mutations thus allow cells to grow and divide in an uncontrolled manner. p14<sup>ARF</sup> protects the p53 tumour suppressor protein from being degraded (see below).

#### **TP53 (tumour protein p53), inactivating point mutation**

p53 is a tumour suppressor protein that stops cells from dividing too fast, or causes damaged or mutated cells that might otherwise become tumour cells to undergo apoptosis (cell suicide). It is often mutated in pancreatic tumours, meaning that mutated cells do not undergo apoptosis and that unregulated cell division occurs instead.

#### **SMAD4 (Sma/mothers against decapentaplegic family member 4), inactivating mutation or deletion**

The SMAD4 protein is a transcription factor (it regulates transcription of other genes) activated by signalling from the membrane-bound TGFβ (transforming growth factor beta) protein. The TGFβ pathway carries signals from the extracellular environment to the nucleus and affects how cells respond to such signals by inducing the production of new proteins. *SMAD4* deletions in pancreatic tumorigenesis can cause cells to proliferate in an uncontrolled manner.

#### **BRCA2 (breast cancer 2, early onset)**

The *BRCA2* gene encodes the breast cancer type 2 susceptibility protein (BRCA2). It is essential for the repair of double-stranded DNA breaks by homologous recombination, and its loss results in chromosomal instability.

compounds identified at earlier stages to be tested for their pharmacology, toxicity and efficacy. The successful evaluation of therapies in the preclinical setting greatly depends on the robustness and predictive ability of preclinical models, which include both *in vitro* and *in vivo* systems (Fig. 2). However, tumour complexity is not accounted for in *in vitro* systems, although co-culture models have been developed that, for instance, involve culturing cancer cells with fibroblasts, immune cells or endothelial cells (Wilding and Bodmer, 2014). *In vitro* drug testing also does not account for the effect of pharmacokinetics and drug metabolism on the activity of a compound nor for its toxicity. Historically, *in vivo* anti-cancer drug evaluation has been carried out in xenograft models (see Box 2), which can be easily and rapidly generated in immunodeficient mice by the implantation of tumour cells or of tissues into ectopic or orthotopic sites (Richmond and Su, 2008). More recently, patient-specific xenografts, which replicate features of individual patient tumours, have been developed to evaluate personalized treatment options (Rubio-Viqueira et al., 2006; Shu et al., 2008; Siolas and Hannon, 2013). Although of lower cost to generate, useful for higher throughput approaches, and complementary to genetically engineered models in comparing mouse and human tumours, xenograft models lack a functional immune system, and produce tumours of reduced complexity and cellular diversity, which could contribute to the fact that drug test results obtained in xenograft systems (as well as in *in vitro* systems) do not correlate well with efficacy testing in humans. In fact, only a small percentage of cancer patients in Phase 1 clinical trials respond to therapies as predicted (Roberts et al., 2004). The disparity

### Box 2. Glossary of terms

**Adenosquamous:** refers to a cancer type containing both gland-like cells and squamous cells (very thin, flattened cells).

**Anaplastic:** cells with abnormal morphology and loss of ordered orientation, compared to normal differentiated cells.

**Cachexia:** a wasting syndrome characterized by loss of weight, fat and muscle mass that is not reversed nutritionally.

**CD3:** a cell surface molecule that associates with the T-cell receptor to allow its activation. The presence of CD3 on the surface of all T cells at all stages of development makes it a good marker for T cells in tissue sections.

**Colloid:** glue like – refers to highly mucinous tumours (mucins are glycoproteins found in secretions).

**CRISPR/Cas:** a system used for gene editing and gene regulation. The Cas9 protein causes DNA breaks, and CRISPRs (clustered regularly interspaced short palindromic repeats) are stretches of DNA with a spacer that target a specific gene. Delivery of CRISPR guide RNAs and Cas9 into a cell allows the genome to be cut at the desired location.

**Dysplasia:** the enlargement of a tissue or organ by the proliferation of abnormal cells.

**Flp-FRT recombinase system:** a site-specific recombination system used to control the spatial expression of transgenes. It consists of flippase (Flp) recombinase, which targets FLP recombinase target (*FRT*) sequences that are placed at either end of a gene or region of interest.

**Fluorouracil:** an antimetabolite chemotherapeutic agent that is a pyrimidine analogue that irreversibly inhibits the nucleotide synthetic enzyme thymidylate synthase.

**Gemcitabine:** a deoxycytidine analogue used as the standard of care for pancreatic cancer. It is activated by phosphorylation, and the di- and triphosphate forms are responsible for its cytotoxicity. It inhibits ribonucleotide reductase, and also competes with deoxycytidine 5-triphosphate (dCTP) for incorporation into DNA during replication. It causes DNA damage and induces apoptosis.

**Haemorrhagic ascites:** the accumulation of blood-stained fluid in the peritoneum.

**Irinotecan:** a cytotoxic chemotherapeutic that inhibits topoisomerase 1, resulting in inhibition of DNA replication and transcription.

**Laparotomy:** a surgical incision in the abdominal wall to gain access into the abdominal cavity.

**Nanoparticle albumin-bound paclitaxel (nab-paclitaxel):** a paclitaxel formulation that uses albumin, the main protein of human blood plasma, to bind paclitaxel and to facilitate its transport out of the bloodstream and into the tumour. Studies show that this formulation increases the therapeutic efficacy of paclitaxel compared to its conventional formulation.

**Nuclear atypia:** abnormal cell nuclei, e.g. often by size, shape or staining pattern.


**Oxaliplatin:** a platinum-based chemotherapeutic agent. It leads to cross-linking of DNA, thereby inhibiting DNA synthesis and transcription.

**Sarcomatoid:** a histological tumour subtype characterized by spindle-shaped tumour cells.

**Transposon (or transposable element):** a short DNA sequence that can alter its position within the genome, thereby causing genetic changes.

**Xenograft:** model generated by the injection or implantation of human cancer cells or tissues into ectopic or orthotopic sites to generate tumours in immunocompromised mice.

between preclinical data and clinical studies can be attributed to various factors, including differences in pharmacokinetics, pharmacodynamics and metabolism, as well as a failure to accurately model the tumour microenvironment (Becher and Holland, 2006; Gopinathan and Tuveson, 2008; Sharpless and Depinho, 2006; Zhang et al., 2013). In pancreatic cancer, in particular, tumours are demonstrably stromal in nature, and the complex interactions between tumour and stromal cells might alter




**Fig. 1. Progression of pancreatic cancer in the KPC model recapitulates the human disease.** (A) In KPC mice, the conditional expression of mutant *Kras*<sup>G12D</sup> and *Trp53*<sup>R172H</sup> is controlled by a pancreas-specific Cre (*Pdx1-cre* in the model described here). In the absence of Cre, a transcriptional and translational STOP cassette flanked by loxP sites (LSL) silences the expression of mutant *Kras*<sup>G12D</sup> and *Trp53*<sup>R172H</sup>. When Cre is expressed in the pancreas, the STOP cassette is excised and the mutant alleles are expressed. The coloured boxes represent exons, and the asterisk (\*) indicates the exon in which the mutation is present. The concomitant expression of mutant *Kras* and *Trp53* in the murine pancreas results in pre-invasive pancreatic intraepithelial neoplasia (PanIN), which progress to pancreatic ductal adenocarcinoma (PDAC). (B) Haematoxylin and eosin (H&E) staining of normal pancreatic ducts in wild-type mice showing that they consist of a single layer of flat, low cuboidal epithelial cells with basal nuclei (arrows). (C-G) H&E staining in KPC mice. (C) In PanIN-1B, papillary or micropapillary projections develop in the ducts (arrows), otherwise these lesions are similar to PanIN-1A (not shown here). (D) More advanced PanIN-2 is characterized by nuclear abnormalities, including loss of polarity (black and white arrows), nuclear overcrowding, enlarged nuclei and rare mitoses (white arrow). (E) PanIN-3, ductal carcinoma *in situ*, is the highest grade of neoplasm and is associated with several abnormalities, including: papillary architecture with loss of nuclear polarity; occasional aberrant mitoses; nuclear abnormalities; large prominent nucleoli; and cribriforming (small clusters of epithelial cells budding into the lumen and necrosis in the lumen) (arrows). (F) PDAC, the resulting carcinoma, exhibits a glandular phenotype with duct-like structures of varying degrees of differentiation, and can exhibit adenosquamous or sarcomatoid histology. Substantial nuclear abnormalities occur and glands appear embedded in the tumour stroma (arrowheads) with completely random organization (arrows). Tumour cells can be observed next to arteries, with perineural and vascular invasion often seen. Necrotic debris can be seen in the lumen of the gland. (G) In advanced disease, metastatic spread is common, particularly to the liver (Liver met). Metastases often exhibit a glandular histology similar to well-differentiated PDAC. Arrow shows a metastatic deposit in mouse liver.

the efficacy of therapeutic agents. The desmoplastic stroma might also act as a barrier to the delivery of agents, such as gemcitabine (Olive et al., 2009), or as a source of survival cues that confer resistance to therapy (Vonlaufen et al., 2008; Xu et al., 2014).

Genetically engineered mouse models (GEMMs) offer an alternative to *in vitro* and xenograft models, and are currently being used to study tumour biology and responses to therapy. Mice are the preferred species for genetic manipulation because of their genetic tractability and because mice carry 99% of the same genes as humans (Mouse Genome Sequencing et al., 2002). GEMMs exist for several epithelial tumour types, including prostate, lung, breast, colon and pancreatic cancers (Frese and Tuveson, 2007). They are generally developed through the introduction of genetic mutations either in oncogenes or tumour suppressors that are associated with specific tumour types, often using conditional

strategies that allow for tissue-specific regulation of these genes. GEMMs can therefore faithfully recapitulate some human cancers in terms of their genetics and phenotype. They can thus be used to study tumour biology, initiation and progression, and to test the action and efficacy of anti-cancer drugs at various time points during disease progression.

In this Review, we describe different GEMMs of pancreatic cancer and their utility for understanding the progression of PDAC and for identifying therapeutic targets. We focus in particular on one of the most widely used GEMMs of pancreatic cancer, the LSL-*Kras*<sup>G12D</sup>; LSL-*Trp53*<sup>R172H</sup>; *Pdx1-cre* (KPC) model, and its use in the preclinical testing of anti-cancer agents. Finally, we discuss the importance of GEMMs in translating research findings to the clinic, and highlight their limitations and potential opportunities for their improvement.



**Fig. 2. Schema of the drug discovery and development pipeline.** The initial stages of the pipeline focus on the discovery and validation of newly identified disease-associated drug targets. Target validation is carried out using *in vitro* and *in vivo* approaches to confirm the relevance of the target in the disease being studied. This is followed by the identification of lead compounds through high-throughput or focused screens of chemical libraries or of naturally occurring molecules, or by structure-based rational drug design. The next stage is lead optimization, where the identified compound is subjected to chemical modifications to improve its pharmacological properties. Optimized lead compounds are then carried forward into preclinical testing, where pharmacology, toxicity and efficacy are assessed. Preclinical testing can occur *in vitro*, in 2- or 3-dimensional cell culture assays, or *in vivo*, in either xenografts or animal models, including genetically engineered mouse models (GEMMs). Promising therapies identified here are taken forward into the clinic. Preclinical models thus provide a bridge to the clinic, and are a requisite part of the drug development pipeline. For more detailed descriptions of the different stages of this pipeline, we refer readers to several recent reviews (Herter-Sprie et al., 2013; Hughes et al., 2011; Kamb et al., 2007; Kenakin, 2003; Pritchard et al., 2003).

### GEMMs of pancreatic cancer: unravelling cancer mechanisms

Many GEMMs of pancreatic cancer have been created (see Table 1) and several feature the deletion or introduction of a mutation into a relevant tumour suppressor gene, often in the context of an activating mutation in *Kras* (see Box 1). Although mutations in *Kras* are a requisite event in the initiation of pancreatic disease, additional genetic events are required to induce tumour formation. Knockout studies have been conducted in the context of mutant *Kras*, with and without additional tumour suppressor mutations, revealing the role of these additional mutations in pancreatic tumour development. These studies have shown, for example, that mutations in *Trp53* and loss of the *Cdkn2a* locus or *Smad4* accelerate PDAC development in the context of mutant *Kras* (see Box 1), but with differing histologies (Aguirre et al., 2003; Bardeesy et al., 2006; Izeradjene et al., 2007). Monoallelic *Trp53* loss accelerates tumour development with the same kinetics as mutant *Trp53<sup>R172H</sup>*, but mutant *Trp53<sup>R172H</sup>* also drives metastatic behaviour in pancreatic tumours (Morton et al., 2010c). When *Brca2* (see Box 1) is deleted in the presence of an activating *Kras* mutation, PDAC formation is suppressed owing to chromosomal instability and apoptosis (Rowley et al., 2011). However, when *Trp53* and *Brca2* are both deleted, mice are more likely to develop PDAC, at reduced latency (Rowley et al., 2011). Moreover, in the absence of functional p53, *Brca2* deletion can cooperate with activated *Kras* mutation to drive pancreatic tumorigenesis (Morton et al., 2011; Rowley et al., 2011; Skoulidis et al., 2010). These studies in GEMMs highlight that human PDAC-associated genetic mutations drive PDAC progression, in cooperation with mutant *Kras*, and are not simply bystander mutations.

In addition to the genes mentioned above, several proteins and pathways have been identified that either promote or suppress PDAC progression, and their effects on tumour development have been studied, some of which are summarized in Table 2. Other GEMMs have shed light on the development of different histological subtypes of the disease. For instance, cystic lesions of the pancreas, such as

intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs), occur in humans and can progress to invasive cancer if untreated. GEMMs have shown that loss of transcriptional intermediary factor 1 gamma (*TIF1 $\gamma$* ) or brahma-related gene-1 (*Brg1*) results in cystic lesions in the pancreas (Vincent et al., 2009; von Figura et al., 2014). *TIF1 $\gamma$*  is a nuclear protein, the molecular function of which is poorly understood, with existing evidence suggesting that it might regulate TGF $\beta$  signalling positively and negatively (Dupont et al., 2005; Dupont et al., 2009; He et al., 2006). *Brg1* is the catalytic ATPase component of the SWI/SNF chromatin remodelling complexes, and is therefore involved in gene transcriptional regulation, with evidence suggesting that it acts as a tumour suppressor in a variety of human cancers (Wong et al., 2000; Izeradjene et al., 2007; Vincent et al., 2009; von Figura et al., 2014). Although candidate gene approaches such as those described above have provided valuable information about the associations between individual genes and specific PDAC phenotypes, forward genetic screens such as those based on the use of transposon-mediated mutagenesis (see Box 2) have also helped to identify previously unknown pathways of potential relevance in tumour development in an unbiased manner (Mann et al., 2012; Perez-Mancera et al., 2012).

Despite their advantages, these models are not without some limitations. For example, mutant genes may be expressed in the entire pancreas through the use of embryonic pancreatic promoters such as *Pdx-1* and *p48* (Hingorani et al., 2003, 2005; Westphalen and Olive, 2012), but the leakiness of these promoters may result in off-target pathologies in other tissues (Gades et al., 2008; Hingorani et al., 2003, 2005). There is, therefore, a need to develop improved GEMMs of PDAC that overcome such limitations. Recently, an inducible *Kras<sup>G12D</sup>* model has been developed that allows for the conditional and reversible expression of oncogenic *Kras* in the pancreas (Collins et al., 2012a; Ying et al., 2012). This model has been used to study the role of activated *Kras* in maintaining established tumours, and the mechanisms by which it acts (Collins et al., 2012a,b; Ying et al., 2012). Indeed, results obtained from this model have identified the activation of Yap1 (Yes-associated

**Table 1. Genetically engineered mouse models of pancreatic cancer**

Name	Mutation	Phenotype	References
KC model: <i>Kras</i> <sup>G12D</sup> ; <i>Cre</i>	Oncogenic <i>Kras</i>	Full spectrum of pre-invasive PanIN, progressing to invasive and metastatic PDAC at low frequency	Hingorani et al., 2003
KPC models: <i>Kras</i> <sup>G12D</sup> ; <i>Trp53</i> mutant; <i>Cre</i>	Oncogenic <i>Kras</i> ; heterozygous <i>Trp53</i> mutation	Pancreatic cancer with 100% penetrance, with all the associated features of the disease, including metastases to the liver, diaphragm and lungs, cachexia, and haemorrhagic ascites	Hingorani et al., 2005
<i>Kras</i> <sup>G12D</sup> ; <i>Trp53</i> <sup>fllox</sup> ; <i>Cre</i>	Oncogenic <i>Kras</i> ; heterozygous deletion of <i>Trp53</i>	Pancreatic cancer with a median survival similar to that of KPC mice. Lack of metastasis compared to KPC mice	Morton et al., 2010c
KPPC models: <i>Kras</i> <sup>G12D</sup> ; <i>Trp53</i> <sup>fllox/fllox</sup> ; <i>Cre</i> or <i>Kras</i> <sup>G12D</sup> ; <i>Trp53</i> <sup>mut/mut</sup> ; <i>Cre</i>	Oncogenic <i>Kras</i> ; homozygous mutations or deletions of the <i>Trp53</i> allele	Very rapid tumour development; greatly reduced median survival (usually ~60 days) compared with that of mice carrying heterozygous deletion or mutation of <i>Trp53</i> ; multifocal tumours, jaundice, ascites and local invasion occur; metastasis is not a common feature	Morton et al., 2010c
<i>Kras</i> <sup>G12D</sup> ; <i>TGF-βR2</i> <sup>fllox</sup> ; <i>Cre</i>	Oncogenic <i>Kras</i> ; homozygous deletion of <i>Tgfr2</i>	Does not impede pancreatic development; rapidly accelerates the development of well-differentiated pancreatic cancer with associated weight loss, haemorrhagic ascites and jaundice; metastatic spread is common, particularly to the liver	Ijichi et al., 2006
<i>Kras</i> <sup>G12D</sup> ; <i>Cdkn2a</i> <sup>fllox</sup> ; <i>Cre</i>	Oncogenic <i>Kras</i> ; homozygous or heterozygous deletion of the <i>Cdkn2a</i> locus (encodes p16 and p19 <sup>ARF</sup> )	Results in rapid tumour development and replicates several clinical features of PDAC; local invasion is extensive but, similar to the KPPC models, metastasis is not a common feature; heterozygous <i>Cdkn2a</i> loss extends the latency of tumour progression and increases the likelihood of metastasis; histologically, there is a higher number of sarcomatoid, undifferentiated tumours in models with disruption of the <i>Cdkn2a</i> locus	Aguirre et al., 2003; Bardeesy et al., 2006
<i>Kras</i> <sup>G12D</sup> ; <i>Pten</i> <sup>fllox</sup> ; <i>Cre</i>	Oncogenic <i>Kras</i> ; heterozygous <i>Pten</i> loss	Dramatically accelerates PanIN and tumour development, with a median survival of 3.5 months; tumours are locally invasive, but metastasis in this model is relatively rare	Hill et al., 2010; Kennedy et al., 2011
<i>Kras</i> <sup>G12V</sup> ; <i>Elastase-tTA/tetO-Cre</i> ± <i>Ink4a/Arf</i> <sup>fllox</sup> ± <i>Trp53</i> <sup>fllox</sup>	Expression of oncogenic <i>Kras</i> <sup>G12V</sup> ; deletion of the <i>Cdkn2a</i> locus or of <i>Trp53</i> can also be added	Expression of oncogenic <i>Kras</i> <sup>G12V</sup> in acinar and centroacinar pancreatic cells during embryogenesis results in the formation of PanINs that progress to PDAC; expression in adult mice, however, results in tumorigenesis only in the context of chronic pancreatitis; deletion of either the <i>Cdkn2a</i> locus or of <i>Trp53</i> accelerates disease progression	Guerra et al., 2007; Guerra et al., 2011
<i>Elastase-tva</i> ; <i>Cdkn2a</i> <sup>-/-</sup> +RCAS-PyMT/cMyc	Deletion of the <i>Cdkn2a</i> locus; expression of <i>Myc</i> or <i>PyMT</i>	Viral delivery of specific oncogenes to 'acinar' and 'centroacinar cells' in neonatal mice induces different tumour types; <i>PyMT</i> induces pancreatic acinar or ductal carcinomas, whereas <i>Myc</i> induces exclusively endocrine tumours, suggesting targeting of one or more types of multipotent progenitor cells	Lewis et al., 2003

The models listed in this table are a sample of mouse PDAC models. In particular, they include those that are driven by the most commonly occurring genetic alterations in human pancreatic cancer, and those that are used for assessing therapeutic agents. The expression of these genes is driven by pancreas-specific *Cre* alleles.

RCAS, replication-competent ASLV long terminal repeat (LTR) with a splice acceptor; *tva*, tumour virus A; *PyMT*, polyoma middle T antigen; *tTA*, tetracycline transactivator protein.

protein 1) – a transcriptional co-activator in the Hippo pathway that controls cell proliferation, apoptosis and thus organ size, and is frequently overexpressed and activated in different cancers (Zhang et al., 2014) – as a potential bypass mechanism to overcome the dependence of PDAC on oncogenic *Kras* (Kapoor et al., 2014). Although this model is useful, it is important to note that the inducible *Kras* is encoded by a transgene, therefore resulting in an extra copy of *Kras* not driven from the endogenous promoter.

Another recently published model has made use of the alternate *Flp-FRT* recombinase system (see Box 2). Thus far, the genetic

studies carried out in GEMMs of PDAC have involved germline knockouts or *Cre*-dependent alleles that are expressed/deleted at the same time as the initiating oncogenic events. These approaches interfere with tumour initiation and progression; therefore, preventative rather than therapeutic approaches are modelled by gene modulation. The *Flp-FRT* recombinase system will enable the generation of GEMMs in which the activation or deletion of genes of interest is under the control of different enzymes, and therefore more amenable to individual manipulation (DeCant et al., 2014; Schönhuber et al., 2014). Indeed, *Kras* activation and *Trp53* deletion

**Table 2. Proteins and signalling pathways contributing to pancreatic cancer development**

Name	Function	Impact on PDAC development	References
Ataxia telangiectasia mutated (ATM)	Serine/threonine kinase involved in DNA-damage repair, particularly of DNA double-strand breaks	<i>ATM</i> deletion in the KC model increases neoplastic changes in the pancreas, enhances epithelial-to-mesenchymal transition (EMT) via modulation of TGF $\beta$ signalling and decreases survival	Russell et al., 2015
B-cell-specific Moloney murine leukaemia virus insertion site 1 (BMI1)	Member of the polycomb group of repressor proteins, and is involved in the regulation of histone ubiquitylation and gene repression	Conditional knockout of <i>Bmi1</i> in the KC background abrogates PanIN formation independent of <i>Cdkn2a</i> status. <i>Bmi1</i> knockdown in PDAC cell lines results in impaired detoxification of reactive oxygen species	Bednar et al., 2015
Cathepsin B	A ubiquitously expressed lysosomal protease belonging to the cysteine cathepsin family, and is involved in a number of normal biological processes, including protein turnover, apoptosis and extracellular-matrix remodelling. Upregulated in a number of human malignancies, and is often mislocalized to the plasma membrane and secreted in the extracellular space	Cathepsin B loss decreases PanIN burden and PanIN proliferation in the context of oncogenic Kras. In the KPC model, the loss of cathepsin B increases survival and decreases liver metastasis	Gopinathan et al., 2012
c-Jun N-terminal protein kinase (JNK)	JNK proteins are members of the mitogen activated protein kinase (MAPK) family, and are activated by growth factors, cytokines, G-protein coupled receptor (GPCR) agonists and environmental stresses. They regulate various functions, including cell growth, survival and apoptosis	Two of the direct activators of JNK are MAPK kinase 4 (MKK4) and MKK7. Conditional deletion of <i>MKK4</i> and <i>MKK7</i> in the murine pancreas impairs acinar regeneration and accelerates Kras-driven tumorigenesis	Davies et al., 2014
Endothelial nitric oxide synthase (eNOS)	Constitutively expressed protein that generates nitric oxide from the oxidation of L-arginine. It is regulated by transcriptional and post-translational modifications	Variable levels of eNOS expression are seen in PanIN and PDAC. <i>eNOS</i> ablation decreases mutant Kras-driven PanIN development, and results in a trend towards increased survival of mice in the KPC background	Lampson et al., 2012
Hedgehog (Hh) signalling	The Hh pathway is important in development, during which it regulates cell growth and survival, cell fate, and body patterning. In the absence of Hh, signalling is inhibited by Patched (Ptc) binding to the Smoothed (Smo) receptor. Hh binds to Ptc to relieve the inhibition of Smo, resulting in activation of the Gli transcription factor family. The pathway is activated inappropriately in many cancer types	Loss of <i>Gli1</i> inhibits PanIN progression and PDAC development in the context of mutant Kras. Conversely, <i>Gli1</i> loss in the context of Kras and <i>Trp53</i> mutations promotes tumour progression and decreases survival. Inhibition of Smo was initially thought to extend survival in combination with gemcitabine. However, further work showed that Hh signalling, via its effect on the tumour stroma, restrains tumours and inhibition of the pathway accelerates tumour growth	Lee et al., 2014; Mills et al., 2013; Mills et al., 2014; Rhim et al., 2014
Liver kinase B1 (LKB1 or STK11)	Originally identified as a tumour suppressor gene associated with Peutz-Jeghers syndrome. It is a serine-threonine kinase and regulates cell growth and metabolism in response to nutrient changes, by phosphorylating adenine monophosphate-activated protein kinase (AMPK)	<i>Lkb1</i> heterozygosity accelerates PDAC in KC mice. Uniquely, homozygous deletion of <i>Lkb1</i> in the pancreas is sufficient to initiate tumour development, in the absence of another initiating oncogenic event. Mechanistically, <i>Lkb1</i> deficiency decreases the expression of the two tumour suppressor proteins p53 and p21 in PanIN lesions	Hezel et al., 2008; Morton et al., 2010a
Lysyl oxidase (LOX)	Extracellular copper-dependent enzyme that cross-links collagen and elastin, increasing tissue stiffness. It is thought to play a role in metastasis in some epithelial cancers	Overexpression of LOX is associated with poor prognosis in patients. In the KPC model, LOX family members are overexpressed in metastatic disease. <i>LOX</i> knockdown decreases PDAC cell invasion <i>in vitro</i> . Treatment of KPC mice with an anti-LOX antibody slows tumorigenesis in combination with gemcitabine and decreases metastasis	Miller et al., 2015

Continued

Table 2. Continued

Name	Function	Impact on PDAC development	References
N-cadherin	Calcium-dependent glycoprotein belonging to the cadherin superfamily. Stimulates the migration and invasion of cells, and its aberrant expression in cancer cells increases their motility and invasiveness	Heterozygous, but not homozygous, <i>N-cadherin</i> loss in the KPC model increases survival	Su et al., 2012
Notch signalling	Crucial for cell fate decisions in development. The four notch genes encode cell surface receptors. Ligand binding to the receptors results in proteolytic cleavage to release the Notch intracellular domain (NICD), which translocates to the nucleus, binds the DNA-binding protein CSL and induces transcription of Notch target genes, including <i>Hes</i> and <i>Hey</i> . Aberrant activation of the Notch pathway contributes to oncogenesis	Notch2 and Hes1 are upregulated during PanIN development in Kras mutant pancreata. Ablation of <i>Notch2</i> , but not <i>Notch1</i> , halts PanIN progression, results in mucinous cystic neoplasm (MCN)-like lesions in the pancreas, and increases survival. Therapeutic inhibition of Notch signalling causes vascular regression, inducing tumour hypoxia and widespread necrosis, even in the absence of improved gemcitabine delivery	Mazur et al., 2010; Cook et al., 2012
Nuclear factor erythroid 2-related factor 2 (Nrf2)	Nrf2 is a basic leucine zipper transcription factor that regulates the expression of antioxidant genes in response to cellular stressors, thereby controlling levels of reactive oxygen species (ROS). Although activation of Nrf2 protects against damage and a wide range of diseases, it is increased in, and can aid the progression of, several types of cancer	<i>Nrf2</i> deletion results in decreased PanIN formation in Kras-mutant pancreata, with existing PanIN demonstrating decreased proliferation and increased senescence compared to Nrf2-expressing PanIN	DeNicola et al., 2011
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)	NF-κB proteins are transcription factors involved in a large number of physiological processes such as growth, apoptosis, inflammatory responses and development. They are activated in a number of malignancies. NF-κB is negatively regulated by interaction with the inhibitor of IκB kinase (Ikk) complex	Deletion of <i>IKK2</i> in the pancreas in the context of oncogenic Kras inhibits PanIN progression	Maniati et al., 2011
Phosphatase and tensin homolog (Pten)	Negatively regulates the phosphoinositide 3-kinase (PI3K)–protein kinase B (Akt)–mechanistic target of rapamycin (mTOR) signalling pathway, which controls cell metabolism, growth and proliferation, and, as such, is deregulated in many cancers	Deletion of <i>Pten</i> in the context of oncogenic Kras accelerates pancreatic tumorigenesis	Hill et al., 2010; Kennedy et al., 2011
Retinoblastoma (Rb)	Tumour suppressor protein. It binds and inhibits the E2F transcription factors, thereby preventing G1-S cell cycle progression. Its function is dysregulated in several cancers	Deletion of <i>Rb</i> cooperates with oncogenic Kras to drive early PanIN and mucinous cystic neoplasm (MCN) development, rapid progression to PDAC, and decreased survival. <i>Rb</i> deletion is associated with inflammatory infiltrates in the pancreas and dysregulation of p53	Carriere et al., 2011
Signal transducer and activator of transcription 3 (STAT3)	STAT proteins are typically tyrosine-phosphorylated by Janus-activated kinases (JAKs) in response to cytokines and growth factors. STAT3 plays an important role in the regulation of inflammation, stem-cell self-renewal and cancer. Constitutive activation of STAT3 has been reported in PDAC cell lines, as well as in human PDAC specimens	STAT3 activation occurs at multiple stages of Kras-induced pancreatic tumorigenesis. Its deletion in the murine pancreas decreases oncogenic-Kras-induced acinar-to-ductal metaplasia and PanIN formation, and its knockdown decreases orthotopic PDAC tumour growth and proliferation. Conversely, aberrant Stat3 activation in the pancreas accelerates tumour development	Corcoran et al., 2011
Sma/mothers against decapentaplegic family member 4 (SMAD4/DPC4)	Smad4 is a tumour suppressor belonging to the Smad family. It mediates signals from the transforming growth factor beta (TGFβ) pathway and suppresses epithelial cell growth	Heterozygous deletion of <i>Smad4</i> concomitant with oncogenic Kras in the pancreas induces mucinous cystic neoplasms (MCNs). Homozygous <i>Smad4</i> loss accelerates progression of MCNs, but with less invasion and metastasis than in the KPC model	Izeradjene et al., 2007; Whittle et al., 2015

Continued

Table 2. Continued

Name	Function	Impact on PDAC development	References
		Concomitant <i>Kras</i> and <i>Trp53</i> mutation with <i>Dpc4</i> deletion results in PDAC with the classical PanIN-to-PDA progression. However, the metastatic burden in these mice remains low compared with KPC mice. The Runx3 transcription factor was identified as a driver of metastasis in PDAC	
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)	Pro-apoptotic ligand belonging to the tumour necrosis factor (TNF) superfamily. Binding of TRAIL to its receptors induces apoptosis via death-inducing silencing complexes (DISCs), leading to caspase activation	Conditional deletion of <i>TRAIL-receptor</i> ( <i>TRAIL-R</i> ) decreases PanIN burden in the KC model, and increases survival and decreases metastasis in KPC mice. Loss of TRAIL-R results in decreased activation of Rac1 in tumour cells	von Karstedt et al., 2015
Ubiquitin specific peptidase 9, X-linked (USP9X)	Deubiquitinase that regulates the stability of several proteins, including $\beta$ -catenin, E-cadherin, Notch, mTOR, MCL1, Itch and Smad4. It therefore impacts on a number of cellular processes, including survival, apoptosis, polarity and chromosome segregation	Usp9X was identified in a forward genetic screen using sleeping beauty transposon-mediated insertional mutagenesis in the KC background. Loss of Usp9X promotes transformation and protects pancreatic cancer cells from anoikis (a form of programmed cell death) <i>in vitro</i> . Deletion of Usp9X in the KC model accelerates pancreatic tumour development	Perez-Mancera et al., 2012

can be temporally separated in the pancreas using a combination of the *Cre-lox* and *Flp-FRT* systems. In *Pdx1-Flp; FSF-Kras<sup>G12D/+</sup>; FSF-R26<sup>CAG-CreERT2/+</sup>; Trp53<sup>lox/lox</sup>* mice (KPF), the deletion of *Trp53* 2 months after the expression of oncogenic *Kras* in the pancreas induces rapid multifocal tumour development (Schönhuber et al., 2014). The *Flp-FRT* system was also used to show that Pdpk1 (3-phosphoinositide-dependent protein kinase 1) deletion in mutant-*Kras*-expressing pancreata blocks PanIN progression (Schönhuber et al., 2014). An alternative method for generating mouse models uses the CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR-associated proteins) gene-editing system (see Box 2) to mutate tumour suppressor genes directly *in vivo*, thereby obviating the need for embryonic stem cell targeting (Sanchez-Rivera et al., 2014; Xue et al., 2014). This approach has recently been demonstrated in the pancreas, where CRISPR-mediated targeting of liver kinase B1 (*Lkb1*) in mice led to tumour growth in conjunction with oncogenic *Kras*, phenocopying the effect of genetic deletion of *Lkb1* (Chiou et al., 2015). In this study, the authors also induced PDAC development in the murine pancreas by administering adenoviral-*Cre* and lentiviral-*Cre* to express oncogenic *Kras* and delete *Trp53* (Chiou et al., 2015), rather than by the widely used transgenic or knock-in *Cre* alleles mentioned above.

GEMMS have also proven their utility in preclinical settings. In particular, they can be used to study how particular genetic lesions influence responses to therapies, thereby potentially identifying specific patient populations that might benefit from treatment. For instance, our group has used the *Kras; Pten* mouse model, in which tumours have high levels of mTOR (mammalian target of rapamycin) signalling, to test the efficacy of an mTOR inhibitor (Morran et al., 2014). Inhibitors of mTOR signalling have failed in clinical trials of all-comers in pancreatic cancer, where patients are not selected based on the presence of specific mutations. However, cases of efficacy have been reported when patients have mutations in the mTOR pathway (Morran et al., 2014), and our findings support these results and suggest that specific patients might benefit from treatment with these inhibitors. Inhibition of hedgehog signalling, a pathway involved in the generation of the tumour

stroma, has been studied in the *Kras; Ink4/Arf<sup>fllox</sup>; Cre* model, in which it increases survival (see Table 1) (Feldmann et al., 2008). In addition, the *Kras; Tgfbr2<sup>fllox</sup>; Cre* pancreatic cancer model (see Table 1) has been used to assess the efficacy of the EGFR (epidermal growth factor receptor) inhibitor erlotinib, as well as the effect of cancer-associated fibroblast depletion. The depletion of cancer-associated fibroblasts accelerates pancreatic cancer development and decreases survival in this model (Miyabayashi et al., 2013; Ozdemir et al., 2014). The response to a given therapeutic or genetic intervention might vary in PDAC models carrying different genetic alterations. For instance, EGFR ablation prevents tumour development in the background of *Cdkn2a* deletion, but only delays it when p53 is lost (Navas et al., 2012), and erlotinib in *Kras; Tgfbr2<sup>fllox</sup>; Cre* mice increases survival in combination with gemcitabine, as described above (Miyabayashi et al., 2013). Taken together with the studies mentioned above, the use of GEMMs carrying different genetic alterations to assess therapeutic targets and agents might be a useful approach to identify subsets of patients who are likely to respond to specific therapies.

The above is a very brief summary of some of the studies done using GEMMs of pancreatic cancer (Guerra and Barbacid, 2013), because an exhaustive discussion of this subject is beyond the scope of this Review. In the next sections, we describe in greater detail the KPC model and its use in preclinical settings because it represents the most common GEMM of PDAC used in this context. We discuss important insights that have emerged from such studies, as well as their clinical relevance and limitations.

#### KPC model: its uses for testing novel cancer therapies

Traditionally, KPC mice are generated by the concomitant expression of oncogenic *Kras<sup>G12D</sup>* and of *Trp53* harbouring a conditional point mutation (*Trp53<sup>R172H</sup>*), both driven by a pancreas-specific *Cre*, the *Pdx1-cre* transgene, which is expressed in all cells of the pancreas from an early stage of embryonic development (Fig. 1A). KPC mice were first described in 2005 (Hingorani et al., 2005). These mutant mice develop the complete spectrum of pre-invasive PanIN, as well as end-stage pancreatic cancer (Fig. 1B-G) with 100% penetrance and with a much shorter latency relative to




models that express oncogenic *Kras*<sup>G12D</sup> alone (Hingorani et al., 2003). The KPC model also exhibits the clinical features of advanced disease, including loss of body conditioning resembling cachexia, haemorrhagic ascites (see Box 2), and metastases to the liver, lungs, peritoneum and lymph nodes (Hingorani et al., 2005). Histopathologically, the tumours tend to be highly stromal with dense desmoplasia and a high degree of chromosomal instability, but sarcomatoid and anaplastic histologies also occur (see Box 2) (Hingorani et al., 2005). A single mouse can have a tumour with different histological components but this considerable intra- and inter-tumour heterogeneity recapitulates that seen in the human disease. As with other GEMMs, the KPC model is a useful tool to advance our understanding of pancreatic cancer biology, particularly given its genetic and histological similarity to the human disease. In addition, it is probably the most widely used of all GEMMs in evaluating preclinical therapeutic agents. In this Review, the term 'KPC' is used to refer primarily to mice harbouring the *Trp53*<sup>R172H</sup> mutation and the *Pdx1-cre* transgene as described above. However, different *Trp53* mutations, such as *Trp53*<sup>R270H</sup>, and other pancreas-specific *Cre* alleles, such as *Ptf1a-Cre* (also called *p48-Cre*), can also be used to drive tumour development in the pancreas.

In this section, we discuss how the KPC model is utilised in both chemopreventive and interventional settings, which are designed to

address different clinical questions (Fig. 3). Chemoprevention studies aim to evaluate the effects of dietary compounds or therapeutic agents that can prevent tumour initiation or that can slow or arrest tumour development. They also include epidemiological studies to identify factors that can increase or reduce the risk of developing cancer. By contrast, interventional studies are designed to evaluate the effect of a treatment – or treatment combinations – on tumour progression and metastasis (early intervention studies) or on established tumours (late intervention studies). They are thus relevant for identifying treatments that can reverse, slow or arrest cancer once it is fully established.

### Chemoprevention

Several chemoprevention studies have been conducted in the *LSL-Kras*<sup>G12D</sup>; *Pdx1-Cre* (KC) model, in which oncogenic *Kras* alone is expressed in the pancreas, as well as in KPC mice. In this setting, mice with early-onset pancreatic disease (generally consisting of early-stage PanIN) are treated very early and prior to the onset of final-stage PDAC. In published studies, the age at enrolment varies from weaning to 10 weeks in KC mice and from weaning to 6 weeks in the KPC model, and the effect of a treatment is assessed either at pre-determined time points (to evaluate the effect on cancer initiation) or at the disease end point (to evaluate the effect on overall survival) (Bai et al., 2011; Chugh et al., 2012;



**Fig. 3. Enrolment scheme for chemoprevention and intervention studies in KPC mice.** In preclinical studies using *LSL-Kras*<sup>G12D</sup>; *LSL-Trp53*<sup>R172H</sup>; *Pdx1-Cre* (KPC) mice, different approaches are used to address different clinical questions. Grey arrows indicate no intervention; green arrows indicate pre-treatment monitoring; and blue arrows indicate treatment assessment. (A) Chemoprevention studies aim to evaluate dietary compounds or therapeutic agents that prevent tumour initiation or slow/arrest tumour development. Mice are enrolled between weaning and 6 weeks of age and, at this stage, usually present with early-stage PanIN. Treatments can be assessed at pre-determined time points or can continue until end point (to evaluate survival). (B) In early intervention studies, which are used to test anti-metastatic therapies, treatment is initiated when mice are 10-12 weeks old, when they commonly have early and late PanINs and occasional tumours. Treatment can last for a fixed period or can continue until end point. (C) Later intervention studies are performed on animals bearing established tumours and are thus relevant for identifying treatments that can reverse, slow or arrest cancer once fully established. These studies require more elaborate monitoring of mice, including manual palpation and ultrasound to monitor tumour size and progression. Treatment can begin when tumours reach the enrolment size for a study. Depending on tumour size, treatment can be short (9-11 days) or long (up to 45 days) (see main text for more detail). (D) Optimal design for intervention studies in KPC mice, incorporating serial sampling to allow pre- and post-treatment assessments of tumour and blood samples.

Husain et al., 2013; Keenan et al., 2014; Lampson et al., 2012; Li et al., 2013; Liao et al., 2013; Morton et al., 2010b; Plentz et al., 2009; Yip-Schneider et al., 2013). For example, KPC mice have a lower tumour burden and increased survival time when treated from 4 weeks of age with atorvastatin, a cholesterol-lowering competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A (HMG CoA) reductase (Liao et al., 2013). A similar outcome was seen when treatment was initiated at 5 weeks of age with sulindac, a non-steroidal anti-inflammatory drug (NSAID), which is an inhibitor of aldo-keto reductase family member 1B10 (AKR1B10), a protein that is overexpressed in human PDAC (Li et al., 2013). The favourable results reported in these two studies might have been caused by the inhibition of PanIN progression. However, later disruption of tumour development and maintenance, or a continuous effect throughout the disease process, cannot be ruled out and further work is needed to dissect these effects. Epidemiological experiments have also been performed in the KPC model and in other GEMMs, including analysis of the effect of diet, nicotine and aspirin on tumour development (Hermann et al., 2014; Lanza-Jacoby et al., 2013; Philip et al., 2013). Nicotine administration accelerates Kras-induced PanIN progression in the pancreas, with increased proliferation in PanIN in nicotine-treated mice. Mechanistically, nicotine results in the activation of Akt-ERK-Myc signalling and the subsequent downregulation of Gata6 (Hermann et al., 2014). Intermittent and chronic calorie restriction in the KC model decreases PanIN progression, with fewer PanIN-2 and PanIN-3 lesions observed. Proliferation in PanIN was also significantly reduced as a consequence of calorie restriction (Lanza-Jacoby et al., 2013). Conversely, a high-fat diet increased stromal content and accelerated pancreatic tumour progression, with cyclooxygenase-2 (Cox2) playing an important role in this process (Philip et al., 2013).

#### Early intervention

Early intervention studies are carried out on mice of a fixed age, without predetermining whether or not they have advanced tumours. Mice are generally enrolled on a study between 10-12 weeks of age (Plassmeier et al., 2013). At this stage, most KPC mice in a cohort would not have advanced PDAC but instead a mix of early and late PanINs and occasional tumours. Treatment in this setting generally occurs for longer periods of time relative to treatment in late intervention studies, and can continue until the disease end point, or for a fixed period of time after which the mice are allowed to age with no further intervention. These early intervention studies thus provide a means to test for drugs that can prevent metastases formation. This is not possible using late intervention protocols, when metastases have already developed. Xenograft 'metastasis' models also cannot be used for such tests because they do not recapitulate the stroma that characterises pancreatic cancer, which likely contributes to the metastatic phenotype.

Early intervention studies can also provide insight into the pathways that are important for PDAC initiation and development, and, additionally, can help us to understand whether the early perturbation of signalling pathways affects metastasis. For example, the inhibition of Src kinase with Dasatinib, a drug used in some forms of leukaemia, with treatment beginning in 70-day-old KPC mice until disease end point, significantly decreased the formation of metastases, albeit without an effect on primary tumour growth or overall survival. Thus, although it might not prevent primary tumour progression, Src inhibition represents a potential anti-metastatic strategy for treating PDAC (Morton et al., 2010b). In

another study, treatment of 70-day-old KPC mice with a LOX-blocking antibody decreased tumorigenesis in combination with gemcitabine, and decreased metastatic burden (Miller et al., 2015). Treatment of KPC mice from 8 weeks of age with the smoothened inhibitor IPI926 demonstrated that long-term inhibition of hedgehog signalling actually accelerates tumour development and decreases survival (Rhim et al., 2014), whereas treatment of KPC-*Brcal* mice at the same time point with the DNA demethylating drug 5-aza-2'-deoxycytidine (decitabine) significantly inhibited tumour growth (Shakya et al., 2013). However, one important consideration is that early intervention studies involve extended treatment, often prior to the existence of frank carcinoma. Tumours developing under these circumstances might evolve to circumvent inhibition, and therefore might be different molecular and biological entities to the tumours that form in untreated mice. Therefore, a favourable outcome in this setting does not indicate that the therapy will successfully inhibit an established tumour, and experiments with promising agents might need to be repeated in a late intervention setting.

Given that many pancreatic cancer patients die from distant metastases even after surgical removal of primary tumours (Heinemann and Boeck, 2008), it is important to test anti-metastatic therapies under these conditions. Thus, we and others are now trialling the excision of primary tumours from the pancreas of mice in order to improve our testing of anti-metastatic therapies; these studies are still at an early stage.

#### Later intervention

As previously mentioned, at the time of diagnosis, individuals with PDAC usually present with late-stage carcinoma. Thus, in evaluating a novel cancer therapy or therapy combination, it is important to assess efficacy on already established tumours, either in terms of survival or by clinical and molecular parameters. In preclinical settings, this requires the identification of tumour-bearing mice prior to the initiation of treatment. The KPC model has a variable latency, which necessitates the use of manual palpation and non-invasive imaging modalities, both to identify animals that carry tumours and to determine tumour size. The schema in Fig. 3C outlines the typical monitoring and screening of KPC mice in late intervention studies (Sastra and Olive, 2013). Beginning at approximately 2 months of age, mice are manually palpated weekly to detect any masses in the abdomen and, with experience, tumours as small as 2 mm or less can be identified by this method. When a mass is detected by palpation, high-resolution ultrasound is used to confirm the presence of a tumour and to measure its size. Ultrasound can also be used to follow tumours over the course of treatment, and volumetric measurements can be performed to establish whether tumour growth is altered in response to therapy (Sastra and Olive, 2013). Treatment can begin when tumours reach a size that makes a mouse eligible for enrolment into a late intervention study.

Several therapeutic studies have been published using KPC mice with different approaches to target tumours (Beatty et al., 2011; Cook et al., 2012; Courtin et al., 2013; Frese et al., 2012; Jacobetz et al., 2013; Neesse et al., 2013; Olive et al., 2009; Provenzano et al., 2012). Mice enrolled in these studies had varying tumour sizes, between 2-10 mm in diameter, with intervention beginning when tumours are 2-5 mm, 4-6 mm, 6-9 mm or 5-10 mm for individual studies published. The Hedgehog (Hh) and Notch signalling pathways are two developmental pathways that are activated in pancreatic cancer. When these signalling pathways are inhibited in the KPC model, in combination with treatment with gemcitabine,

the mice have improved survival relative to controls, although the mechanism of action differs between the two pathways. The inhibition of Hh signalling decreased the stromal content of KPC tumours, effectively increasing the delivery and/or efficacy of gemcitabine (Olive et al., 2009). By comparison, the inhibition of Notch signalling seemed to induce vascular regression, causing tumour hypoxia and widespread necrosis, even in the absence of improved gemcitabine delivery (Cook et al., 2012).

Targeting the stromal component, either by depleting the extracellular matrix component glycosaminoglycan hyaluronic acid (HA) or by inhibiting the matrix protein CTGF (connective tissue growth factor), was also effective in combination with gemcitabine. Whereas HA depletion by PEGPH20 resulted in improved vasculature and increased gemcitabine delivery, blocking CTGF decreased the expression of the pro-survival protein XIAP (X-linked inhibitor of apoptosis) and induced the killing of tumour cells (Jacobetz et al., 2013; Neesse et al., 2013). The depletion of HA described for the treatment of larger tumours has also been tested in tumours of 2-5 mm diameter, and has similarly improved survival in combination with gemcitabine (Provenzano et al., 2012). PEGPH20 is currently being assessed in a randomized Phase 2 clinical trial assessing its efficacy as a first-line therapy against metastatic pancreatic cancer in combination with gemcitabine/nab-paclitaxel compared to gemcitabine/nab-paclitaxel alone (<https://clinicaltrials.gov/ct2/show/NCT01839487>). PEGPH20 initially proved problematic clinically, with a high rate of blood clots and other thromboembolic events observed in the PEGPH20 arm. Following a protocol amendment, the interim data from the trial was recently revealed to be promising, with increased median progression-free survival and overall response rate in the PEGPH20 arm compared with the gemcitabine/nab-paclitaxel arm. There was also a trend towards improvement in median overall survival (<http://www.halozyne.com/Investors/News-Releases/>; News Release on 31st May 2015).

In another preclinical study, the efficacy of nab-paclitaxel was assessed in combination with gemcitabine in a limited-duration experiment (Frese et al., 2012). In this study, nab-paclitaxel effectively altered gemcitabine metabolism by decreasing the levels of the primary gemcitabine-metabolizing enzyme, cytidine deaminase (CDA). This increased gemcitabine stability and, uniquely, it induced tumour regression (Frese et al., 2012).

Another approach to targeting PDAC involves the immune system. Administration of AMD3100, a C-X-C chemokine receptor type 4 (CXCR4) inhibitor, in combination with the inhibitory checkpoint antagonist anti-PD-L1 (anti-programmed death 1 ligand 1), results in the loss of p53-positive tumour cells and in the accumulation of CD3<sup>+</sup> T-cells (see Box 2) in the tumour area (Feig et al., 2013). In another study, the immune system was modulated using a CD40 agonist. The resulting tumour shrinkage was mediated by macrophages, and the expected influx of T cells into the tumour did not occur (Beatty et al., 2011). Further work showed that tumour-derived granulocyte-macrophage colony stimulating factor (GM-CSF) regulates the recruitment of Gr-1<sup>+</sup>CD11b<sup>+</sup> myeloid cells, which suppress antigen-specific T-cell responses (Bayne et al., 2012). These studies exemplify a few of the many approaches that are being considered in the targeting of PDAC, including combinatorial approaches that target tumour cells and the individual components of the stroma.


Established tumours in the KPC model undergo rapid growth. With tumours of 5-10 mm diameter, the median survival of untreated mice is around 9-11 days. As a consequence, treatment regimens tend to be of a limited duration, even where combination

treatments induce a statistically significant increase in survival. Short-term studies can also be carried out with fixed durations of treatment. These enable in-depth mechanistic analyses of the therapeutic effects of a given treatment, but might also be useful in cases where longer-term treatment is not feasible. Nab-paclitaxel, for instance, is formulated using human albumin and induces anaphylaxis in mice, thereby necessitating short-term treatment (Frese et al., 2012). In general, using smaller tumours tends to lengthen the treatment period and consequently drug exposure. For instance, with tumours of 2-3 mm diameter, the median survival of untreated mice is approximately 45 days (Provenzano et al., 2012). This approach permits the long-term effects of drug exposure to be assessed, both on the tumour and on the host, which is not possible in mice with larger tumours. This also models the condition of individuals who present at an early stage at the clinic.

#### Factors that influence response to therapy

Irrespective of tumour size, interventional approaches are generally labour- and resource-intensive, requiring a large mouse colony and a substantial investment of time to screen and monitor treated animals. Particularly in the case of large tumours, mice are also lost to ill health prior to enrolment, thereby extending the enrolment period, and in fixed-duration experiments, mice that do not reach the required time point owing to short survival times need to be replaced.

When assessing responses to therapeutic agents, varying results can be obtained depending on tumour size. There is a lack of studies examining the differences in tumour response based on initial tumour size. However, our preliminary observations suggest that, in KPC mice with tumours of 6-9 mm diameter at the time of enrolment in the study, the tumour growth in the first 7 days post-enrolment correlates with survival, perhaps indicating that 7 days is a useful time point to assess early responses to treatment. As another example, there is generally not a significant difference in survival between vehicle- and gemcitabine-treated cohorts in KPC mice with large tumours (Olive et al., 2009). However, when mice with smaller tumours (3-6 mm mean diameter) are treated with gemcitabine, and compared to vehicle-treated controls, gemcitabine seems to have a beneficial effect on their survival (Fig. 4). This might be due to poor drug perfusion in large tumours because of



**Fig. 4. Effects of tumour size on response to treatment in the KPC model.** Gemcitabine imparts a small yet significant survival benefit in mice with smaller tumours (our unpublished observations). Mice were enrolled on study when tumours reached 3-6 mm mean diameter. Mice were treated with either saline or gemcitabine (100 mg/kg body weight) intraperitoneally twice per week until end point. 12 mice were enrolled per cohort. The median survival post-enrolment is indicated for each cohort in the figure. The Log-rank test was conducted using GraphPad Prism ( $P=0.0236$ ).

their well-developed desmoplastic stroma (Olive et al., 2009). Another example of differing outcomes is seen with the use of the matrix-depleting agent PEGPH20, which was independently assessed in the two studies involving mice with large or small tumours mentioned above (Jacobetz et al., 2013; Provenzano et al., 2012). In combination with gemcitabine, PEGPH20 improved survival in both circumstances but with some differences. Smaller tumours (2-5 mm diameter) were characterized by a significant remodelling of their stroma, including a depletion of fibrillar collagen and  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA)-positive fibroblasts. By contrast, the stromal content of larger tumours at end point remained similar between the control and treated groups. These findings suggest that primary tumour burden is not the sole determinant of treatment outcome and that this outcome can be influenced by the presence of a well-established tumour stroma. Other factors that might affect therapeutic outcome and survival include tumour location, extent of metastatic disease and occurrence of cachexia (Bachmann et al., 2008; Neoptolemos et al., 2004; Watanabe et al., 2004), which together reflect the complex and multifaceted nature of advanced pancreatic cancer.

Duration of treatment can also affect therapeutic outcome. As previously described, Hh pathway inhibition was first reported to decrease stromal content in KPC mice with large tumours, thereby increasing gemcitabine delivery to tumours and extending survival when administered in combination with gemcitabine (Olive et al., 2009). Unfortunately, despite a promising Phase 1 clinical trial, these results were not borne out by the Phase 2 study. Following the failure of this clinical trial, further work was carried out in the KPC model to understand the discrepancy. In this study (Rhim et al., 2014), mice were treated for an extended period of time, and the preclinical data recapitulated what was seen in the clinic, with inhibition of Hh signalling decreasing survival rather than improving it. This indicates that the prolonged inhibition of signalling pathways might have different effects to those intended, which would not be picked up by a 'large tumour' intervention study (Rhim et al., 2014). Given the shorter treatment duration in mice with large tumours, apparent treatment outcomes might simply be indicative of acute responses of tumours to therapy (in the case of Hh inhibition, the initial depletion of the stroma and the corresponding increase in gemcitabine delivery to tumours). In reality, extended exposure to compounds might be required to unveil the consequences of a treatment's indirect effects or the development of resistance through the modulation of signalling or by other mechanisms.

The genetic background and the specific genetic alterations of the mice that are used in a study are two other factors to consider when evaluating response to therapy. As has been discussed earlier, the outcome of genetic and therapeutic studies can vary depending on the underlying genetic alterations in the mouse models. Understanding these differences, and identifying cohorts that are likely to respond to a given therapy, might inform the selection of patient populations in clinical trials.

#### **Translating mechanistic information from mice to humans: limitations and opportunities**

Improving success rates in clinical trials depends on the use of robust and predictive preclinical models. Owing to its genetic and histopathological similarity to human PDAC, the KPC model is relevant for evaluating therapies and for understanding treatment mechanisms. However, the examples mentioned above illustrate the importance of determining the best way of using preclinical models, so that the obtained results accurately reflect clinical outcome. Results obtained from studies using the KPC model suggest that

mice bearing smaller tumours might be of particular relevance for survival studies because their use allows sufficient time for adverse effects to become apparent. Care must also be taken when interpreting the results of such studies, in particular focusing on change in tumour volume and not absolute tumour size.

Another important question that requires consideration is whether the tumour at the end of the treatment period is the same biological entity as the initial tumour at the start of the study. Until now, tumour comparisons have been static and carried out between treatment cohorts (e.g. vehicle versus drug) because it has not been possible to obtain pre- and post-treatment tumour samples. Recently, however, a laparotomy (see Box 2) method has been developed that allows tumour biopsies to be obtained surgically (Sastru and Olive, 2014) from KPC tumours. This technique allows the paired comparison of pre- and post-treatment samples, for example, to analyze whether the continued accumulation of mutations alters the activity of signalling pathways targeted by drugs. This technique might also enable biopsies to be obtained and examined prior to, during and after treatment, and then compared to determine how a tumour is modulated by treatment and whether it remains the same entity in terms of its histopathology and signalling pathways. Although this approach might remove the need to use large cohorts to account for inter-tumour heterogeneity and biological variation, small individual biopsies might not be representative of the entire tumour due to heterogeneity.

A key strength of preclinical models is the ability to gain mechanistic insight into the tested therapies, in a manner that would not be possible in a clinical setting. For example, fixed-time-point pharmacodynamic studies can be conducted, allowing the immediate (24-48 h), intermediate (7 days) and long-term effects of treatment to be compared, for example on signalling pathways and tumour characteristics such as proliferation, apoptosis, etc. Therapies that target metastasis can be tested in early and advanced disease, and the effect of drugs on organs other than the pancreas can be assessed. Haematological and biochemical analyses can complement molecular investigations both in pharmacodynamic and survival studies. Routine imaging including high-resolution ultrasound as discussed above, but also magnetic resonance imaging (MRI), positron emission tomography and micro-computed tomography, can be carried out to evaluate tumour progression and dissemination. Preclinical testing in GEMMs also has the potential to identify tumour biomarkers that can be used to either predict drug response or to stratify patients for treatment (Singh et al., 2012).

In addition to targeting the primary tumour and disseminated disease, studies can be conducted on symptoms, such as cachexia, which are associated with PDAC. The importance of the stroma and immune compartments in tumours can also be investigated. Recent work has, in fact, shown that the stromal compartment in PDAC might have a role in suppressing pancreatic tumours (Ozdemir et al., 2014; Rhim et al., 2014); however, careful interpretation of data is required when tumours are initiated in the absence of stroma, or where depleting the stroma results in a substantial inflammatory response. As mentioned above, there are also several approaches for targeting the immune system that are being explored to enhance the anti-tumour immune response, such as activation of CD40, inhibition of chemokine (C-X-C motif) ligand 12 (CXCL12) and vaccines (Beatty et al., 2011; Feig et al., 2013; Keenan et al., 2014). Given that chemotherapy is a mainstay of PDAC treatment, combinations with chemotherapy should be considered when assessing new drugs preclinically. Indeed, most preclinical work to date has focused on the use of gemcitabine in combination with various agents. The changing landscape of treatment in the clinic

necessitates the need for a more up-to-date approach to chemotherapy in the preclinical models. The FOLFIRINOX regimen might be challenging to model in mice, but new therapies can be tested in combination with gemcitabine/nab-paclitaxel to further develop current treatments.

Despite their advantages, GEMMs have several drawbacks, including the length of time needed to generate mutant mice carrying several genetic alterations. In conditional GEMMs, such as the KPC model, genetic alterations are often activated simultaneously in a large number of cells during development in the mouse, even though they are used as models of sporadic, non-inherited human cancers. In addition, models such as KPC mice cannot be used to study the cell-of-origin of pancreatic cancer. This has required the use of alternative promoters, such as the inducible tetracycline-inducible *Elastase-cre* or the Nestin promoter (Guerra and Barbacid, 2013). Tissue-specific promoters, such as *Pdx1-cre*, are sometimes expressed in other tissues, resulting in off-target pathologies, such as papillomas and lymphoma. Tumour development in GEMMs can also take a long time and occurs with variable latency. Unlike xenografts, tumour monitoring might require advanced imaging, including high-resolution ultrasound and MRI. Although useful information can be obtained from these imaging modalities, they require specialist training and equipment that is not always easily available. In all, preclinical testing in GEMMs is significantly more expensive than the testing performed in *in vitro* culture or xenografts. Nevertheless, their advantages, as discussed here, make them a very promising preclinical platform, and a potential means of assessing complex treatment modalities and of identifying anti-cancer drug combinations to evaluate in the clinic.

## Conclusions

Owing to their similarity to human disease, KPC mice and other GEMMs of pancreatic cancer can be excellent tools to assess therapeutics and to understand mechanisms of drug action and resistance in tumours. They have not yet been completely validated in terms of their ability to predict the outcome of trials; however, as discussed in this Review, there is extensive evidence of their relevance in preclinical research (Singh et al., 2010). In order to remain clinically relevant, preclinical testing in these models must keep abreast of developments in the clinical sphere. GEMMs might also provide information relevant for patient stratification in clinical trials. If we are to derive benefit from these models, consideration must be given to the way in which they are used, including the timing and scheduling of treatment, because this might affect experimental outcomes and therefore the predictive accuracy of the model. Any insight gained from such preclinical models must be extended to the clinic to demonstrate their relevance. The models that are currently available are relevant; however, they will become more predictive of clinical outcomes as we gain more knowledge and understanding of the various factors that affect response to therapy. In the future, it is likely that more attention will be paid to the model used in preclinical testing, the stage of intervention and, importantly, what constitutes a response that is robust enough to provide confidence for translation to the clinic.

This article is part of a subject collection on Model Systems in Drug Discovery: from Bench to Patient. See related articles in this collection at <http://dmm.biologists.org/cgi/collection/drugdiscovery>

## Acknowledgements

We would like to thank Professor David Tuveson, who supervised some of the work presented as unpublished observations, which was conducted by A. Gopinathan in

his laboratory. We also thank Paul Mackin, Lisa Young, Steven Kupczak, Maureen Cronshaw and other past and present members of the Tumour Models Core and BRU at the Cancer Research UK Cambridge Institute for providing support for therapeutic studies.

## Competing interests

The authors declare no competing or financial interests.

## Author contributions

All authors contributed to planning and drafting the manuscript.

## Funding

Funding for the work in Figure 1 was provided by Cancer Research UK and supported by the Cancer Research UK Glasgow Centre and the BSU facilities at the Cancer Research UK Beatson Institute. Funding was also provided by the Cancer Research UK Cambridge Institute grant C14303/A17197 and the Cambridge Cancer Centre.

## References

- Adler, G. (2004). Has the biology and treatment of pancreatic diseases evolved? *Best Pract. Res. Clin. Gastroenterol.* **18**, 83-90.
- Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S. and DePinho, R. A. (2003). Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. *Genes Dev.* **17**, 3112-3126.
- Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N. and Perucho, M. (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. *Cell* **53**, 549-554.
- Bachmann, J., Heiligensetzer, M., Krakowski-Roosen, H., Buchler, M. W., Friess, H. and Martignoni, M. E. (2008). Cachexia worsens prognosis in patients with resectable pancreatic cancer. *J. Gastrointest. Surg.* **12**, 1193-1201.
- Bai, H., Li, H., Zhang, W., Matkowskyj, K. A., Liao, J., Srivastava, S. K. and Yang, G.-Y. (2011). Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D/Pdx1-Cre mice. *Carcinogenesis* **32**, 1689-1696.
- Bardeesy, N., Aguirre, A. J., Chu, G. C., Cheng, K.-H., Lopez, L. V., Hezel, A. F., Feng, B., Brennan, C., Weissleder, R., Mahmood, U. et al. (2006). Both p16 (Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. *Proc. Natl. Acad. Sci. USA* **103**, 5947-5952.
- Bayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z. and Vonderheide, R. H. (2012). Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. *Cancer Cell* **21**, 822-835.
- Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L. et al. (2011). CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. *Science* **331**, 1612-1616.
- Becher, O. J. and Holland, E. C. (2006). Genetically engineered models have advantages over xenografts for preclinical studies. *Cancer Res.* **66**, 3355-3358, discussion 3358-3359.
- Bednar, F., Schofield, H. K., Collins, M. A., Yan, W., Zhang, Y., Shyam, N., Eberle, J. A., Almada, L. L., Olive, K. P., Bardeesy, N. et al. (2015). Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism. *Carcinogenesis* **36**, 730-738.
- Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., Wu, J. et al. (2012). Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature* **491**, 399-405.
- Burris, H. A., III, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J. Clin. Oncol.* **15**, 2403-2413.
- Carriere, C., Gore, A. J., Norris, A. M., Gunn, J. R., Young, A. L., Longnecker, D. S. and Korc, M. (2011). Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions. *Gastroenterology* **141**, 1091-1101.
- Chiou, S. H., Winters, I. P., Wang, J., Naranjo, S., Dudgeon, C., Tamburini, F. B., Brady, J. J., Yang, D., Grüner, B. M., Chuang, C. H. et al. (2015). Pancreatic cancer modeling using retrograde viral vector delivery and *in vivo* CRISPR/Cas9-mediated somatic genome editing. *Genes Dev.* **29**, 1576-1585.
- Chugh, R., Sangwan, V., Patil, S. P., Dudeja, V., Dawra, R. K., Banerjee, S., Schumacher, R. J., Blazar, B. R., Georg, G. I., Vickers, S. M. et al. (2012). A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. *Sci. Transl. Med.* **4**, 156ra139.
- Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galban, S., Galban, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V. and Pasca di Magliano, M. (2012a).

- Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. *J. Clin. Invest.* **122**, 639-653.
- Collins, M. A., Brisset, J.-C., Zhang, Y., Bednar, F., Pierre, J., Heist, K. A., Galbán, C. J., Galbán, S. and Pasca di Magliano, M.** (2012b). Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. *PLoS ONE* **7**, e49707.
- Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C. et al.** (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N. Engl. J. Med.* **364**, 1817-1825.
- Cook, N., Frese, K. K., Bapiro, T. E., Jacobetz, M. A., Gopinathan, A., Miller, J. L., Rao, S. S., Demuth, T., Howat, W. J., Jodrell, D. I. et al.** (2012). Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. *J. Exp. Med.* **209**, 437-444.
- Corcoran, R. B., Contino, G., Deshpande, V., Tzatsos, A., Conrad, C., Benes, C. H., Levy, D. E., Settleman, J., Engelman, J. A. and Bardeesy, N.** (2011). STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. *Cancer Res.* **71**, 5020-5029.
- Courtin, A., Richards, F. M., Bapiro, T. E., Bramhall, J. L., Neesse, A., Cook, N., Krippendorff, B.-F., Tuveson, D. A. and Jodrell, D. I.** (2013). Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. *PLoS ONE* **8**, e67330.
- Davies, C. C., Harvey, E., McMahon, R. F. T., Finegan, K. G., Connor, F., Davis, R. J., Tuveson, D. A. and Tournier, C.** (2014). Impaired JNK signaling cooperates with KrasG12D expression to accelerate pancreatic ductal adenocarcinoma. *Cancer Res.* **74**, 3344-3356.
- DeCant, B. T., Principe, D. R., Guerra, C., Pasca di Magliano, M. and Grippo, P. J.** (2014). Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models. *Front. Physiol.* **5**, 464.
- Dupont, S., Zacchigna, L., Cordenonsi, M., Soligo, S., Adorno, M., Rugge, M. and Piccolo, S.** (2005). Germ-layer specification and control of cell growth by Ectoderm, a Smad4 ubiquitin ligase. *Cell* **121**, 87-99.
- Dupont, S., Mamidi, A., Cordenonsi, M., Montagner, M., Zacchigna, L., Adorno, M., Martello, G., Stinchfield, M. J., Soligo, S., Morsut, L. et al.** (2009). FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. *Cell* **136**, 123-135.
- DeNicola, G. M., Karreth, F. A., Humpston, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S. et al.** (2011). Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. *Nature* **475**, 106-109.
- Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L. et al.** (2013). Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. *Proc. Natl. Acad. Sci. USA* **110**, 20212-20217.
- Feldmann, G. and Maitra, A.** (2008). Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. *J. Mol. Diagn.* **10**, 111-122.
- Feldmann, G., Habbe, N., Dhara, S., Bisht, S., Alvarez, H., Fendrich, V., Beaty, R., Mullendore, M., Karikari, C., Bardeesy, N. et al.** (2008). Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. *Gut* **57**, 1420-1430.
- Frese, K. K. and Tuveson, D. A.** (2007). Maximizing mouse cancer models. *Nat. Rev. Cancer* **7**, 654-658.
- Frese, K. K., Neesse, A., Cook, N., Bapiro, T. E., Lolkema, M. P., Jodrell, D. I. and Tuveson, D. A.** (2012). nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. *Cancer Discov.* **2**, 260-269.
- Gades, N. M., Ohash, A., Mills, L. D., Rowley, M. A., Predmore, K. S., Marler, R. J. and Couch, F. J.** (2008). Spontaneous vulvar papillomas in a colony of mice used for pancreatic cancer research. *Comp. Med.* **58**, 271-275.
- Goldstein, D., El-Maraghi, R. H., Hammel, P., Heinemann, V., Kunzmann, V., Sastre, J., Scheithauer, W., Siena, S., Tabernero, J., Teixeira, L. et al.** (2015). nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. *J. Natl. Cancer Inst.* **107**, dju413.
- Gopinathan, A. and Tuveson, D. A.** (2008). The use of GEM models for experimental cancer therapeutics. *Dis. Model. Mech.* **1**, 83-86.
- Gopinathan, A., DeNicola, G. M., Frese, K. K., Cook, N., Karreth, F. A., Mayerle, J., Lerch, M. M., Reinheckel, T. and Tuveson, D. A.** (2012). Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. *Gut* **61**, 877-884.
- Guerra, C. and Barbacid, M.** (2013). Genetically engineered mouse models of pancreatic adenocarcinoma. *Mol. Oncol.* **7**, 232-247.
- Guerra, C., Schuhmacher, A. J., Canamero, M., Grippo, P. J., Verdager, L., Perez-Gallego, L., Dubus, P., Sandgren, E. P. and Barbacid, M.** (2007). Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. *Cancer Cell* **11**, 291-302.
- Guerra, C., Collado, M., Navas, C., Schuhmacher, A. J., Hernandez-Porras, I., Canamero, M., Rodriguez-Justo, M., Serrano, M. and Barbacid, M.** (2011). Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. *Cancer Cell* **19**, 728-739.
- He, W., Dorn, D. C., Erdjument-Bromage, H., Tempst, P., Moore, M. A. and Massague, J.** (2006). Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. *Cell* **125**, 929-941.
- Heestand, G. M., Murphy, J. D. and Lowy, A. M.** (2015). Approach to patients with pancreatic cancer without detectable metastases. *J. Clin. Oncol.* **33**, 1770-1778.
- Heinemann, V. and Boeck, S.** (2008). Perioperative management of pancreatic cancer. *Ann. Oncol.* **19** Suppl. 7, vii273-vii278.
- Hermann, P. C., Sancho, P., Canamero, M., Martinelli, P., Madriles, F., Michl, P., Gress, T., de Pascual, R., Gandia, L., Guerra, C. et al.** (2014). Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. *Gastroenterology* **147**, 1119-1133.
- Herter-Sprie, G. S., Kung, A. L. and Wong, K.-K.** (2013). New cast for a new era: preclinical cancer drug development revisited. *J. Clin. Invest.* **123**, 3639-3645.
- Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N. and DePinho, R. A.** (2006). Genetics and biology of pancreatic ductal adenocarcinoma. *Genes Dev.* **20**, 1218-1249.
- Hezel, A. F., Gurumurthy, S., Granot, Z., Swisa, A., Chu, G. C., Bailey, G., Dor, Y., Bardeesy, N. and Depinho, R. A.** (2008). Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. *Mol. Cell. Biol.* **28**, 2414-2425.
- Hidalgo, M.** (2010). Pancreatic cancer. *N. Engl. J. Med.* **362**, 1605-1617.
- Hill, R., Calvopina, J. H., Kim, C., Wang, Y., Dawson, D. W., Donahue, T. R., Dry, S. and Wu, H.** (2010). PTEN loss accelerates KrasG12D-induced pancreatic cancer development. *Cancer Res.* **70**, 7114-7124.
- Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A. et al.** (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell* **4**, 437-450.
- Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramandt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S. and Tuveson, D. A.** (2005). Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. *Cancer Cell* **7**, 469-483.
- Hruban, R. H. and Adsay, N. V.** (2009). Molecular classification of neoplasms of the pancreas. *Hum. Pathol.* **40**, 612-623.
- Hruban, R. H., Adsay, N. V., Albores-Saavedra, J., Compton, C., Garrett, E. S., Goodman, S. N., Kern, S. E., Klimstra, D. S., Klöppel, G., Longnecker, D. S. et al.** (2001a). Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. *Am. J. Surg. Pathol.* **25**, 579-586.
- Hruban, R. H., Iacobuzio-Donahue, C., Wilentz, R. E., Goggins, M. and Kern, S. E.** (2001b). Molecular pathology of pancreatic cancer. *Cancer J.* **7**, 251-258.
- Hruban, R. H., Takaori, K., Klimstra, D. S., Adsay, N. V., Albores-Saavedra, J., Biankin, A. V., Biankin, S. A., Compton, C., Fukushima, N., Furukawa, T. et al.** (2004). An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. *Am. J. Surg. Pathol.* **28**, 977-987.
- Hughes, J. P., Rees, S., Kalindjian, S. B. and Philipott, K. L.** (2011). Principles of early drug discovery. *Br. J. Pharmacol.* **162**, 1239-1249.
- Husain, K., Centeno, B. A., Chen, D.-T., Fulp, W. J., Perez, M., Zhang Lee, G., Luetkeke, N., Hingorani, S. R., Sebt, S. M. and Malafa, M. P.** (2013). Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E delta-tocotrienol. *Carcinogenesis* **34**, 858-863.
- Ijichi, H., Chytil, A., Gorska, A. E., Aakre, M. E., Fujitani, Y., Fujitani, S., Wright, C. V. E. and Moses, H. L.** (2006). Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. *Genes Dev.* **20**, 3147-3160.
- Izeradjene, K., Combs, C., Best, M., Gopinathan, A., Wagner, A., Grady, W. M., Deng, C.-X., Hruban, R. H., Adsay, N. V., Tuveson, D. A. et al.** (2007). Kras (G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. *Cancer Cell* **11**, 229-243.
- Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I. et al.** (2013). Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. *Gut* **62**, 112-120.
- Kamb, A., Wee, S. and Lengauer, C.** (2007). Why is cancer drug discovery so difficult? *Nat. Rev. Drug Discov.* **6**, 115-120.
- Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B. et al.** (2014). Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. *Cell* **158**, 185-197.
- Keenan, B. P., Saenger, Y., Kafrouni, M. I., Leubner, A., Lauer, P., Maitra, A., Rucki, A. A., Gunderson, A. J., Coussens, L. M., Brockstedt, D. G. et al.** (2014). A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. *Gastroenterology* **146**, 1784-1794. e1786.
- Kenakin, T.** (2003). Predicting therapeutic value in the lead optimization phase of drug discovery. *Nat. Rev. Drug Discov.* **2**, 429-438.
- Kennedy, A. L., Morton, J. P., Manoharan, I., Nelson, D. M., Jamieson, N. B., Pawlikowski, J. S., McBryan, T., Doyle, B., McKay, C., Oien, K. A. et al.** (2011).

- Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. *Mol. Cell* **42**, 36-49.
- Lampson, B. L., Kendall, S. D., Ancrile, B. B., Morrison, M. M., Shealy, M. J., Barrientos, K. S., Crowe, M. S., Kashatus, D. F., White, R. R., Gurley, S. B. et al. (2012). Targeting eNOS in pancreatic cancer. *Cancer Res.* **72**, 4472-4482.
- Lanza-Jacoby, S., Yan, G., Radice, G., LePhong, C., Baliff, J. and Hess, R. (2013). Calorie restriction delays the progression of lesions to pancreatic cancer in the LSL-KrasG12D; Pdx-1/Cre mouse model of pancreatic cancer. *Exp. Biol. Med.* **238**, 787-797.
- Lee, J. J., Perera, R. M., Wang, H., Wu, D.-C., Liu, X. S., Han, S., Fitamant, J., Jones, P. D., Ghanta, K. S., Kawano, S. et al. (2014). Stromal response to Hedgehog signaling restrains pancreatic cancer progression. *Proc. Natl. Acad. Sci. USA* **111**, E3091-E3100.
- Lewis, B. C., Klimstra, D. S. and Varmus, H. E. (2003). The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer. *Genes Dev.* **17**, 3127-3138.
- Li, H., Yang, A. L., Chung, Y. T., Zhang, W., Liao, J. and Yang, G.-Y. (2013). Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10). *Carcinogenesis* **34**, 2090-2098.
- Liao, J., Chung, Y. T., Yang, A. L., Zhang, M., Li, H., Zhang, W., Yan, L. and Yang, G.-Y. (2013). Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice. *Mol. Carcinog.* **52**, 739-750.
- Maniati, E., Bossard, M., Cook, N., Candido, J. B., Emami-Shahri, N., Nedospasov, S. A., Balkwill, F. R., Tuveson, D. A. and Hagemann, T. (2011). Crosstalk between the canonical NF-kappaB and Notch signaling pathways inhibits Ppargamma expression and promotes pancreatic cancer progression in mice. *J. Clin. Invest.* **121**, 4685-4699.
- Mann, K. M., Ward, J. M., Yew, C. C. K., Kovochich, A., Dawson, D. W., Black, M. A., Brett, B. T., Sheetz, T. E., Dupuy, A. J., Australian Pancreatic Cancer Genome Initiative et al. (2012). Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. *Proc. Natl. Acad. Sci. USA* **109**, 5934-5941.
- Mazur, P. K., Einwachter, H., Lee, M., Sipos, B., Nakhai, H., Rad, R., Zimmer-Strobl, U., Strobl, L. J., Radtke, F., Klöppel, G. et al. (2010). Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. *Proc. Natl. Acad. Sci. USA* **107**, 13438-13443.
- Miller, B. W., Morton, J. P., Pinese, M., Saturno, G., Jamieson, N. B., McGhee, E., Timpson, P., Leach, J., McGarry, L., Shanks, E. et al. (2015). Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. *EMBO Mol. Med.* **7**, 1063-1076.
- Mills, L. D., Zhang, Y., Marler, R. J., Herreros-Villanueva, M., Zhang, L., Almada, L. L., Couch, F., Wetmore, C., Pasca di Magliano, M. and Fernandez-Zapico, M. E. (2013). Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation. *J. Biol. Chem.* **288**, 11786-11794.
- Mills, L. D., Zhang, L., Marler, R., Svingen, P., Fernandez-Barrena, M. G., Dave, M., Bamlet, W., McWilliams, R. R., Petersen, G. M., Faubion, W. et al. (2014). Inactivation of the transcription factor GLI1 accelerates pancreatic cancer progression. *J. Biol. Chem.* **289**, 16516-16525.
- Miyabayashi, K., Ijichi, H., Mohri, D., Tada, M., Yamamoto, K., Asaoka, Y., Ikenoue, T., Tateishi, K., Nakai, Y., Isayama, H. et al. (2013). Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. *Cancer Res.* **73**, 2221-2234.
- Morran, D. C., Wu, J., Jamieson, N. B., Mrowinska, A., Kalna, G., Karim, S. A., Au, A. Y. M., Scarlett, C. J., Chang, D. K., Pajak, M. Z. et al. (2014). Targeting mTOR dependency in pancreatic cancer. *Gut* **63**, 1481-1489.
- Morton, J. P., Jamieson, N. B., Karim, S. A., Athineos, D., Ridgway, R. A., Nixon, C., McKay, C. J., Carter, R., Brunton, V. G., Frame, M. C. et al. (2010a). LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. *Gastroenterology* **139**, 586-597. e581-586.
- Morton, J. P., Karim, S. A., Graham, K., Timpson, P., Jamieson, N., Athineos, D., Doyle, B., McKay, C., Heung, M.-Y., Oien, K. A. et al. (2010b). Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. *Gastroenterology* **139**, 292-303.
- Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G. et al. (2010c). Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. *Proc. Natl. Acad. Sci. USA* **107**, 246-251.
- Morton, J. P., Steele, C. W. and Sansom, O. J. (2011). Timing is everything: Brca2 and p53 mutations in pancreatic cancer. *Gastroenterology* **140**, 1143-1146.
- Mouse Genome Sequencing C, Waterston, R. H., Lindblad-Toh, K., Birney, E., Rogers, J., Abril, J. F., Agarwal, P., Agarwala, R., Ainscough, R., Alexandersson, M. et al. (2002). Initial sequencing and comparative analysis of the mouse genome. *Nature* **420**, 520-562.
- Navas, C., Hernandez-Porras, I., Schuhmacher, A. J., Sibilia, M., Guerra, C. and Barbacid, M. (2012). EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. *Cancer Cell* **22**, 318-330.
- Neesse, A., Frese, K. K., Bapiro, T. E., Nakagawa, T., Sternlicht, M. D., Seeley, T. W., Pilarsky, C., Jodrell, D. I., Spong, S. M. and Tuveson, D. A. (2013). CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. *Proc. Natl. Acad. Sci. USA* **110**, 12325-12330.
- Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F. et al. (2004). A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. *N. Engl. J. Med.* **350**, 1200-1210.
- Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D. et al. (2009). Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. *Science* **324**, 1457-1461.
- Ozdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V. et al. (2014). Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. *Cancer Cell* **25**, 719-734.
- Perez-Mancera, P. A., Rust, A. G., van der Weyden, L., Kristiansen, G., Li, A., Sarver, A. L., Silverstein, K. A., Grützmann, R., Aust, D., Rümmele, P. et al. (2012). The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. *Nature* **486**, 266-270.
- Philip, B., Roland, C. L., Daniluk, J., Liu, Y., Chatterjee, D., Gomez, S. B., Ji, B., Huang, H., Wang, H., Fleming, J. B. et al. (2013). A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. *Gastroenterology* **145**, 1449-1458.
- Plassmeier, L., Knoop, R., Waldmann, J., Kesselring, R., Buchholz, M., Fichtner-Feigl, S., Bartsch, D. K. and Fendrich, V. (2013). Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer. *Langenbecks Arch. Surg.* **398**, 989-996.
- Plentz, R., Park, J.-S., Rhim, A. D., Abravanel, D., Hezel, A. F., Sharma, S. V., Gurumurthy, S., Deshpande, V., Kenific, C., Settleman, J. et al. (2009). Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. *Gastroenterology* **136**, 1741-1749. e1746.
- Pritchard, J. F., Jurima-Romet, M., Reimer, M. L. J., Mortimer, E., Rolfe, B. and Cayen, M. N. (2003). Making better drugs: decision gates in non-clinical drug development. *Nat. Rev. Drug Discov.* **2**, 542-553.
- Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D. and Hingorani, S. R. (2012). Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. *Cancer Cell* **21**, 418-429.
- Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palerm, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W. et al. (2014). Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. *Cancer Cell* **25**, 735-747.
- Richmond, A. and Su, Y. (2008). Mouse xenograft models vs GEM models for human cancer therapeutics. *Dis. Model. Mech.* **1**, 78-82.
- Roberts, T. G., Jr, Goulart, B. H., Squitieri, L., Stallings, S. C., Halpern, E. F., Chabner, B. A., Gazelle, G. S., Finkelstein, S. N. and Clark, J. W. (2004). Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. *JAMA* **292**, 2130-2140.
- Rowley, M., Ohashi, A., Mondal, G., Mills, L., Yang, L., Zhang, L., Sundsbak, R., Shapiro, V., Muders, M. H., Smyrk, T. et al. (2011). Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. *Gastroenterology* **140**, 1303-1313. e1301-1303.
- Rubio-Viqueira, B., Jimeno, A., Cusatis, G., Zhang, X., Iacobuzio-Donahue, C., Karikari, C., Shi, C., Danenberg, K., Danenberg, P. V., Kuramochi, H. et al. (2006). An in vivo platform for translational drug development in pancreatic cancer. *Clin. Cancer Res.* **12**, 4652-4661.
- Russell, R., Perkhof, L., Liebau, S., Lin, Q., Lechel, A., Feld, F. M., Hessmann, E., Gaedcke, J., Güthle, M., Zenke, M. et al. (2015). Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition. *Nat. Comm.* **6**, 7677.
- Sanchez-Rivera, F. J., Papagiannakopoulos, T., Romero, R., Tammela, T., Bauer, M. R., Bhutkar, A., Joshi, N. S., Subbaraj, L., Bronson, R. T., Xue, W. et al. (2014). Rapid modelling of cooperating genetic events in cancer through somatic genome editing. *Nature* **516**, 428-431.
- Sastra, S. A. and Olive, K. P. (2013). Quantification of murine pancreatic tumors by high-resolution ultrasound. *Methods Mol. Biol.* **980**, 249-266.
- Sastra, S. A. and Olive, K. P. (2014). Acquisition of mouse tumor biopsies through abdominal laparotomy. *Cold Spring Harb. Protoc.* **2014**, 47-56.
- Schönhuber, N., Seidler, B., Schuck, K., Veltkamp, C., Schachtler, C., Zukowska, M., Eser, S., Feyerabend, T. B., Paul, M. C., Eser, P. et al. (2014). A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. *Nat. Med.* **20**, 1340-1347.

- Shakya, R., Gonda, T., Quante, M., Salas, M., Kim, S., Brooks, J., Hirsch, S., Davies, J., Cullo, A., Olive, K. et al. (2013). Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma. *Cancer Res.* **73**, 885-896.
- Sharpless, N. E. and Depinho, R. A. (2006). The mighty mouse: genetically engineered mouse models in cancer drug development. *Nat. Rev. Drug Discov.* **5**, 741-754.
- Shu, Q., Wong, K. K., Su, J. M., Adesina, A. M., Yu, L. T., Tsang, Y. T. M., Antalfy, B. C., Baxter, P., Perlaky, L., Yang, J. et al. (2008). Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. *Stem Cells* **26**, 1414-1424.
- Siegel, R. L., Miller, K. D. and Jemal, A. (2015). Cancer statistics, 2015. *CA Cancer J. Clin.* **65**, 5-29.
- Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A. C., Devasthali, V., Thompson, J. D., Cheng, J. H., Bou Reslan, H., Ho, C. C. K. et al. (2010). Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. *Nat. Biotechnol.* **28**, 585-593.
- Singh, M., Murriel, C. L. and Johnson, L. (2012). Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. *Cancer Res.* **72**, 2695-2700.
- Siolas, D. and Hannon, G. J. (2013). Patient-derived tumor xenografts: transforming clinical samples into mouse models. *Cancer Res.* **73**, 5315-5319.
- Skoulidis, F., Cassidy, L. D., Pisupati, V., Jonasson, J. G., Bjarnason, H., Eyfjord, J. E., Karreth, F. A., Lim, M., Barber, L. M., Clatworthy, S. A. et al. (2010). Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. *Cancer Cell* **18**, 499-509.
- Su, Y., Li, J., Witkiewicz, A. K., Brennan, D., Neill, T., Talarico, J. and Radice, G. L. (2012). N-cadherin haploinsufficiency increases survival in a mouse model of pancreatic cancer. *Oncogene* **31**, 4484-4489.
- Vincent, D. F., Yan, K.-P., Treilleux, I., Gay, F., Arfi, V., Kaniewsky, B., Marie, J. C., Lepinasse, F., Martel, S., Goddard-Leon, S. et al. (2009). Inactivation of TIF1gamma cooperates with KrasG12D to induce cystic tumors of the pancreas. *PLoS Genet.* **5**, e1000575.
- von Figura, G., Fukuda, A., Roy, N., Liku, M. E., Morris, J. P., IV, Kim, G. E., Russ, H. A., Firpo, M. A., Mulvihill, S. J., Dawson, D. W. et al. (2014). The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. *Nat. Cell Biol.* **16**, 255-267.
- Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjuland, S. A., Ma, W. W., Saleh, M. N. et al. (2013). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N. Engl. J. Med.* **369**, 1691-1703.
- von Karstedt, S., Conti, A., Nobis, M., Montinaro, A., Hartwig, T., Lemke, J., Legler, K., Annewanter, F., Campbell, A. D., Taraborrelli, L. et al. (2015). Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. *Cancer Cell* **27**, 561-573.
- Vonlaufen, A., Joshi, S., Qu, C., Phillips, P. A., Xu, Z., Parker, N. R., Toi, C. S., Pirola, R. C., Wilson, J. S., Goldstein, D. et al. (2008). Pancreatic stellate cells: partners in crime with pancreatic cancer cells. *Cancer Res.* **68**, 2085-2093.
- Warshaw, A. L. and Fernandez-del Castillo, C. (1992). Pancreatic carcinoma. *N. Engl. J. Med.* **326**, 455-465.
- Watanabe, I., Sasaki, S., Konishi, M., Nakagohri, T., Inoue, K., Oda, T. and Kinoshita, T. (2004). Onset symptoms and tumor locations as prognostic factors of pancreatic cancer. *Pancreas* **28**, 160-165.
- Westphalen, C. B. and Olive, K. P. (2012). Genetically engineered mouse models of pancreatic cancer. *Cancer J.* **18**, 502-510.
- Whittle, M. C., Izeradjene, K., Rani, P. G., Feng, L., Carlson, M. A., DelGiorno, K. E., Wood, L. D., Goggins, M., Hruban, R. H., Chang, A. E. et al. (2015). RUNX3 controls a metastatic switch in pancreatic ductal adenocarcinoma. *Cell* **161**, 1345-1360.
- Wilding, J. L. and Bodmer, W. F. (2014). Cancer cell lines for drug discovery and development. *Cancer Res.* **74**, 2377-2384.
- Wong, A. K., Shanahan, F., Chen, Y., Lian, L., Ha, P., Hendricks, K., Ghaffari, S., Iliev, D., Penn, B., Woodland, A. M. et al. (2000). BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. *Cancer Res.* **60**, 6171-6177.
- Xu, Z., Pothula, S. P., Wilson, J. S. and Apte, M. V. (2014). Pancreatic cancer and its stroma: a conspiracy theory. *World J. Gastroenterol.* **20**, 11216-11229.
- Xue, W., Chen, S., Yin, H., Tammela, T., Papagiannakopoulos, T., Joshi, N. S., Cai, W., Yang, G., Bronson, R., Crowley, D. G. et al. (2014). CRISPR-mediated direct mutation of cancer genes in the mouse liver. *Nature* **514**, 380-384.
- Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L. et al. (2012). Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. *Cell* **149**, 656-670.
- Yip-Schneider, M. T., Wu, H., Stantz, K., Agaram, N., Crooks, P. A. and Schmidt, C. M. (2013). Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. *BMC Cancer* **13**, 194.
- Zhang, Y., Chen, L., Yang, J., Fleming, J. B., Chiao, P. J., Logsdon, C. D. and Li, M. (2013). Study human pancreatic cancer in mice: how close are they? *Biochim. Biophys. Acta* **1835**, 110-118.
- Zhang, W., Nandakumar, N., Shi, Y., Manzano, M., Smith, A., Graham, G., Gupta, S., Vietsch, E. E., Laughlin, S. Z., Wadhwa, M. et al. (2014). Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. *Sci. Signal.* **7**, ra42.